Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the … Read more
Oncopeptides AB (publ) (ONPPF) - Net Assets
Latest net assets as of March 2025: $-5.84 Million USD
Based on the latest financial reports, Oncopeptides AB (publ) (ONPPF) has net assets worth $-5.84 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($173.41 Million) and total liabilities ($179.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.84 Million |
| % of Total Assets | -3.37% |
| Annual Growth Rate | 21.71% |
| 5-Year Change | -90.59% |
| 10-Year Change | N/A |
| Growth Volatility | 479.07 |
Oncopeptides AB (publ) - Net Assets Trend (2014–2024)
This chart illustrates how Oncopeptides AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncopeptides AB (publ) (2014–2024)
The table below shows the annual net assets of Oncopeptides AB (publ) from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $54.28 Million | -4.39% |
| 2023-12-31 | $56.78 Million | -80.71% |
| 2022-12-31 | $294.29 Million | +39.56% |
| 2021-12-31 | $210.87 Million | -63.45% |
| 2020-12-31 | $576.90 Million | -27.62% |
| 2019-12-31 | $797.01 Million | +152.35% |
| 2018-12-31 | $315.83 Million | -24.44% |
| 2017-12-31 | $418.00 Million | +1487.15% |
| 2016-12-31 | $26.34 Million | +1112.95% |
| 2015-12-31 | $-2.60 Million | -134.19% |
| 2014-12-31 | $7.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncopeptides AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 552353130500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $5.70 Billion | 10509.13% |
| Total Equity | $54.28 Million | 100.00% |
Oncopeptides AB (publ) Competitors by Market Cap
The table below lists competitors of Oncopeptides AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KJTS
KLSE:0293
|
$48.60 Million |
|
Birko Birlesik Koyunlulular Mensucat Ticaret ve Sanayi AS
IS:BRKO
|
$48.61 Million |
|
Gevelot
PA:ALGEV
|
$48.61 Million |
|
MAYO Human Capital Inc.
TWO:6738
|
$48.62 Million |
|
Stratec SE
PINK:STSEY
|
$48.57 Million |
|
AMIA Co. Ltd.
TW:8438
|
$48.56 Million |
|
Central Plains Bancshares, Inc. Common Stock
NASDAQ:CPBI
|
$48.55 Million |
|
Prevas AB Series B
LSE:0H2J
|
$48.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncopeptides AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 56,780,000 to 54,285,000, a change of -2,495,000 (-4.4%).
- Net loss of 284,607,000 reduced equity.
- Other comprehensive income increased equity by 2,199,000.
- Other factors increased equity by 279,913,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-284.61 Million | -524.28% |
| Other Comprehensive Income | $2.20 Million | +4.05% |
| Other Changes | $279.91 Million | +515.64% |
| Total Change | $- | -4.39% |
Book Value vs Market Value Analysis
This analysis compares Oncopeptides AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.74x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.35x to 0.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.20 | $0.27 | x |
| 2015-12-31 | $-0.07 | $0.27 | x |
| 2016-12-31 | $0.68 | $0.27 | x |
| 2017-12-31 | $10.78 | $0.27 | x |
| 2018-12-31 | $7.36 | $0.27 | x |
| 2019-12-31 | $15.42 | $0.27 | x |
| 2020-12-31 | $9.25 | $0.27 | x |
| 2021-12-31 | $2.80 | $0.27 | x |
| 2022-12-31 | $3.57 | $0.27 | x |
| 2023-12-31 | $0.63 | $0.27 | x |
| 2024-12-31 | $0.36 | $0.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncopeptides AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -524.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -899.29%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 4.50x
- Recent ROE (-524.28%) is below the historical average (-289.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -435.13% | 0.00% | 0.00x | 1.73x | $-33.85 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-53.08 Million |
| 2016 | -434.55% | 0.00% | 0.00x | 2.11x | $-117.08 Million |
| 2017 | -59.24% | 0.00% | 0.00x | 1.15x | $-289.42 Million |
| 2018 | -132.81% | 0.00% | 0.00x | 1.41x | $-451.03 Million |
| 2019 | -92.94% | 0.00% | 0.00x | 1.25x | $-820.41 Million |
| 2020 | -276.43% | -8239.18% | 0.02x | 1.64x | $-1.65 Billion |
| 2021 | -678.30% | -1209.11% | 0.27x | 2.08x | $-1.45 Billion |
| 2022 | -114.83% | -4044.90% | 0.02x | 1.31x | $-367.38 Million |
| 2023 | -438.73% | -707.30% | 0.15x | 4.20x | $-254.79 Million |
| 2024 | -524.28% | -899.29% | 0.13x | 4.50x | $-290.04 Million |
Industry Comparison
This section compares Oncopeptides AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncopeptides AB (publ) (ONPPF) | $-5.84 Million | -435.13% | N/A | $48.58 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |